BACKGROUND: Understanding the earliest central nervous system (CNS) events during human immunodeficiency virus (HIV) infection is crucial to knowledge of neuropathogenesis, but these have not previously been described in humans. METHODS: Twenty individuals who had acute HIV infection (Fiebig stages I-IV), with average 15 days after exposure, underwent clinical neurological, cerebrospinal fluid (CSF), magnetic resonance imaging, and magnetic resonance spectroscopy (MRS) characterization. RESULTS: HIV RNA was detected in the CSF from 15 of 18 subjects as early as 8 days after estimated HIV transmission. Undetectable CSF levels of HIV (in 3 of 18) was noted during Fiebig stages I, II, and III, with plasma HIV RNA levels of 285651, 2321, and 81978 copies/mL, respectively. On average, the CSF HIV RNA level was 2.42 log(10) copies/mL lower than that in plasma. There were no cases in which the CSF HIV RNA level exceeded that in plasma. Headache was common during the acute retroviral syndrome (in 11 of 20 subjects), but no other neurological signs or symptoms were seen. Intrathecal immune activation was identified in some subjects with elevated CSF neopterin, monocyte chemotactic protein/CCL2, and interferon γ-induced protein 10/CXCL-10 levels. Brain inflammation was suggested by MRS. CONCLUSIONS: CSF HIV RNA was detectable in humans as early as 8 days after exposure. CNS inflammation was apparent by CSF analysis and MRS in some individuals during acute HIV infection.
BACKGROUND: Understanding the earliest central nervous system (CNS) events during human immunodeficiency virus (HIV) infection is crucial to knowledge of neuropathogenesis, but these have not previously been described in humans. METHODS: Twenty individuals who had acute HIV infection (Fiebig stages I-IV), with average 15 days after exposure, underwent clinical neurological, cerebrospinal fluid (CSF), magnetic resonance imaging, and magnetic resonance spectroscopy (MRS) characterization. RESULTS:HIV RNA was detected in the CSF from 15 of 18 subjects as early as 8 days after estimated HIV transmission. Undetectable CSF levels of HIV (in 3 of 18) was noted during Fiebig stages I, II, and III, with plasma HIV RNA levels of 285651, 2321, and 81978 copies/mL, respectively. On average, the CSF HIV RNA level was 2.42 log(10) copies/mL lower than that in plasma. There were no cases in which the CSF HIV RNA level exceeded that in plasma. Headache was common during the acute retroviral syndrome (in 11 of 20 subjects), but no other neurological signs or symptoms were seen. Intrathecal immune activation was identified in some subjects with elevated CSF neopterin, monocyte chemotactic protein/CCL2, and interferon γ-induced protein 10/CXCL-10 levels. Brain inflammation was suggested by MRS. CONCLUSIONS: CSF HIV RNA was detectable in humans as early as 8 days after exposure. CNS inflammation was apparent by CSF analysis and MRS in some individuals during acute HIV infection.
Authors: P Vanhems; R Allard; D A Cooper; L Perrin; J Vizzard; B Hirschel; S Kinloch-de Löes; A Carr; J Lambert Journal: Clin Infect Dis Date: 1997-05 Impact factor: 9.079
Authors: P Cinque; L Vago; M Mengozzi; V Torri; D Ceresa; E Vicenzi; P Transidico; A Vagani; S Sozzani; A Mantovani; A Lazzarin; G Poli Journal: AIDS Date: 1998-07-30 Impact factor: 4.177
Authors: J C McArthur; D R Hoover; H Bacellar; E N Miller; B A Cohen; J T Becker; N M Graham; J H McArthur; O A Selnes; L P Jacobson Journal: Neurology Date: 1993-11 Impact factor: 9.910
Authors: L E Davis; B L Hjelle; V E Miller; D L Palmer; A L Llewellyn; T L Merlin; S A Young; R G Mills; W Wachsman; C A Wiley Journal: Neurology Date: 1992-09 Impact factor: 9.910
Authors: Jesus F Salazar-Gonzalez; Maria G Salazar; Brandon F Keele; Gerald H Learn; Elena E Giorgi; Hui Li; Julie M Decker; Shuyi Wang; Joshua Baalwa; Matthias H Kraus; Nicholas F Parrish; Katharina S Shaw; M Brad Guffey; Katharine J Bar; Katie L Davis; Christina Ochsenbauer-Jambor; John C Kappes; Michael S Saag; Myron S Cohen; Joseph Mulenga; Cynthia A Derdeyn; Susan Allen; Eric Hunter; Martin Markowitz; Peter Hraber; Alan S Perelson; Tanmoy Bhattacharya; Barton F Haynes; Bette T Korber; Beatrice H Hahn; George M Shaw Journal: J Exp Med Date: 2009-06-01 Impact factor: 14.307
Authors: Robert A Fuller; Susan V Westmoreland; Eva Ratai; Jane B Greco; John P Kim; Margaret R Lentz; Julian He; Prabhat K Sehgal; Eliezer Masliah; Elkan Halpern; Andrew A Lackner; R Gilberto González Journal: BMC Neurosci Date: 2004-03-05 Impact factor: 3.288
Authors: Lisa M Mangus; Rachel L Weinberg; Audrey C Knight; Suzanne E Queen; Robert J Adams; Joseph L Mankowski Journal: J Neuropathol Exp Neurol Date: 2019-01-01 Impact factor: 3.685
Authors: Peter D Burbelo; Richard W Price; Lars Hagberg; Hiroyu Hatano; Serena Spudich; Steven G Deeks; Magnus Gisslén Journal: J Infect Dis Date: 2018-03-13 Impact factor: 5.226
Authors: Igor Grant; Donald R Franklin; Reena Deutsch; Steven P Woods; Florin Vaida; Ronald J Ellis; Scott L Letendre; Thomas D Marcotte; J H Atkinson; Ann C Collier; Christina M Marra; David B Clifford; Benjamin B Gelman; Justin C McArthur; Susan Morgello; David M Simpson; John A McCutchan; Ian Abramson; Anthony Gamst; Christine Fennema-Notestine; Davey M Smith; Robert K Heaton Journal: Neurology Date: 2014-05-09 Impact factor: 9.910
Authors: Neda Jahanshad; Victor G Valcour; Talia M Nir; Omid Kohannim; Edgar Busovaca; Krista Nicolas; Paul M Thompson Journal: Brain Connect Date: 2012